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is used to identify a subject-specific threshold for abnormality
in the REM variance. A metric that includes the percentage of
REM variance exceeding the threshold relates to RBD.
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AUTOMATED POLYSOMNOGRAPHIC
ASSESSMENT FOR RAPID EYE MOVEMENT
SLEEP BEHAVIOR DISORDER

during the REM sleep time interval or the percentage may be
used in conjunction with a visual PSG score and/or clinical
impression to assess RBD.
Further areas of applicability will become apparent from
the description provided herein. It should be understood that
the description and specific examples are intended for purposes of illustration only and are not intended to limit the
scope of the present disclosure.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of U.S. Provisional
Application No. 60/921,466, filed on Apr. 2, 2007. The disclosure of the above application is incorporated herein by
reference.
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DRAWINGS

FIG. 1 is a flowchart ofa method for diagnosing and assessing rapid eye movement sleep behavior disorder (RBD) in a
patient according to one embodiment of the present discloThis invention was made with govermnent support under 15 sure;
FIG. 2 is a block diagram of a system for diagnosing and
Contract Nos. POI NS! 5655 and MO! RR000042 awarded by
assessing rapid eye movement sleep behavior disorder (RBD)
the National Institutes of Health. The government has rights
in a patient constructed according to one embodiment of the
in the invention.
present disclosure;
20
FIG. 3 graphically illustrates a thirty-second epoch of
FIELD
REM sleep (upper panel), along with a corresponding plot of
calculated EMG variance for each 3-second mini-epoch
The present disclosure relates to methods and systems for
(lower panel);
diagnosing and assessing rapid eye movement sleep behavior
FIG. 4 graphically illustrates electromyographic variance
disorder and related conditions.
25 computed over 3-second mini-epochs through the night (A)
INTRODUCTION
for a subject without a clinical diagnosis ofRBD, and (B) for
a subject with a clinical diagnosis of RBD;
Rapid eye movement (REM) sleep behavior disorder
FIG. 5 graphically illustrates that the computer-generated
(RBD) affects about 0.4% of adults, 0.5% of older adults,
Supra-Threshold REM EMG Activity Metric (STREAM)
33% of patients with newly diagnosed Parkinson's Disease, 30 correlates closely with the visually-based polysomnographic
and 90% of patients with multiple system atrophy. Consescore for RBD severity;
quences can include injury to the patient, threats to the safety
FIG. 6 graphically illustrates that the computer-generated
of a bed partner, and inability to share a bed with a partner.
EMG variance score (A) and visually-generated PSG score
Diagnosis is important because the condition responds well to
(B) show similar ability to separate subjects for whom RBD
treatment, most often with clonazepam. Moreover, RBD may 35 was considered probable or possible (1) or unlikely (0) by
be a harbinger for neurodegenerative conditions such as Parclinicians who interviewed and examined the subjects;
kinson's disease (PD), multiple system atrophy (MSA), or
FIG. 7 graphically illustrates RBD symptom scores
dementia with Lewy bodies (DLB), which together comprise
derived from an International Criteria for Sleep Disordersthe alpha-synucleinopathies. In the absence of RBD, REM
based questionnaire plotted against the computer-generated
sleep without atonia may also signal increased risk for alpha- 40 STREAM score (A) and the visually-generated PSG score
synucleinopathies.
(B);
There is a need for improved methods and systems for the
FIG. 8 graphically illustrates receiver-operator characterdiagnosis of RBD, and for assessment of RBD-like features
istic (ROC) curves for the STREAM and the visually-generthat may predict future development of neurodegenerative
ated PSG score;
disorders. The statements in this section merely provide back- 45
FIG. 9 graphically illustrates that the STREAM during
ground information related to the present disclosure and may
REM sleep on night 1 correlates with STREAM on night 2;
not constitute prior art.
FIG.10 graphically illustrates a quantitative visual scoring
method where the RBD polysonmographic score (PSG
SUMMARY
Score) is plotted against the International Classification of
50 Sleep Disorders-based clinical impression of RBD presence
The present disclosure includes methods and systems
(1) or absence (0); and
related to assessment of rapid eye movement sleep behavior
FIG. 11 graphically illustrates a quantitative visual scoring
disorder and related conditions.
method where the REM (rapid eye movement) sleep behavior
In some embodiments, the present disclosure relates to a
disorder (RBD) polysonmographic score (PSG score) is plotmethod for diagnosing and assessing rapid eye movement 55 ted against the RBD symptom score derived from bed partner
sleep behavior disorder (RBD) in a patient. The method
questionnaires (Quest).
includes measuring at least one physiological signal of the
The drawings described herein are for illustration purposes
patient during at least one rapid eye movement (REM) sleep
only and are not intended to limit the scope of the present
time interval and at least one non-rapid eye movement
disclosure in any way.
(NREM) sleep time interval. The method also includes deter- 60
mining a Variance for the physiological signal within at least
DETAILED DESCRIPTION
one REM sleep time interval and a variance for the physiological signal within at least one NREM sleep time interval.
Polysonmography is a valuable technique in the diagnosis
A threshold based on the NREM variance is established and a
of rapid eye movement sleep behavior disorder (RBD) and in
percentage of REM sleep time intervals with variance above 65 identifying REM sleep without atonia, but interpretation of
the threshold is calculated. The patient may be classified as an
the requisite findings can be highly subjective. In many cases,
RBD candidate when the percentage exceeds the threshold
dream enactment is not directly observed in the sleep laboraGOVERNMENT RIGHTS
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tory. Diagnosis may depend on the polysomnographer's perception of elevated baseline muscle tone or abnormally frequent bursts of discrete muscle activation recorded from the
surface electromyogram (EMG) during REM sleep. Diagnosis based on quantification of these EMG patterns, or some
objective polysomnographic measure ofRBD severity, is less
subjective and more reliable.
In some embodiments, the present disclosure provides
methods and systems to quantify polysomnographic evidence
of RBD severity; to help assess risk for RBD at present; to
help assess risk for development ofRBD in the future; and/or
to help assess the extent to which physiologic features of
RBD are present on the polysomnogram. Embodiments may
include a computer algorithm to identify EMG features of
RBD automatically. The computerized algorithm identifies
polysomnographic evidence of RBD as accurately as visual
scoring methods, including those performed by a polysomnographer and including the methods described by Lapierre
0, Montplaisir J., "Polysomnographic features ofREM sleep
behavior disorder: Development of a scoring method," Neurology 1992; 42:1371-1374 and Consens F B, Chervin RD,
Koeppe RA et al., "Validation of a polysomnographic score
for REM sleep behavior disorder," Sleep 2005; 28(8):993997. The present methods and visual scoring methods show
similar correspondence to clinical and questionnaire evidence ofRBD.
In some embodiments, an automated method is provided
that facilitates objective identification ofRBD based on sleep
studies, including, for example, polysomnograms. The
method may include recording one or more electromyogram
(EMG) signals (non-invasive or invasive) for a subject while
the subject is sleeping. It is envisioned that other physiological signals indicative of muscle activity during sleep, such as
cardiac-related signals, may be used in place ofEMG signals.
Portions of the EMG signal(s) that are recorded during
REM sleep are identified. For example, 30-second epochs of
REM sleep may be identified using a standard visual scoring
method. However, REM sleep phases may be identified either
in this manner or by using automated signal analysis techniques. For example, an automated method for distinguishing
REM and NREM sleep intervals may include using the Morpheus® Clinical Sleep Information System (WideMed, Ltd.,
Herzliya, Israel). The automated method for distinguishing
REM and NREM sleep may be used concurrently with the
present methods to collect and process various physiological
signals, including one or more of the following: electroencephalogram (EEG), electromyogram (EMG), electrooculogram (EOG), and electrocardiogram (ECG), or other physiological signals indicative of wakefulness, REM sleep, and
NREM sleep.
In some embodiments, the EMG signal is partitioned into
predefined time increments (e.g., 3 second mini-epochs) and
a variance measure is calculated for each time increment. The
variance of n data samples x, may be computed as

tone during REM sleep should not exceed the lowest tone
noted during non-REM sleep, operationalized here as the 5th
percentile of the NREM EMG variance. To identify activity
likely to be abnormal, with reference to NREM EMG tone,
the abnormality threshold may be set at 4 times the 5th percentile. Other cut-offs may perform similarly; e.g., 2 to 6
times the 5th percentile. The choice for a specific cut-off is in
no way meant to exclude other choices that can reasonably be
made without alteration of the underlying methodological
concept. This underlying concept is that a patient-specific
EMG variance threshold during REM sleep may be automatically computed (rather than visually and subjectively
assessed) for an individual patient based on that same
patient's muscle tone during sleep more generally, or particularly during non-REM sleep.
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n

(l/(n-1)) ~ (x; -xi, where x
i=l

n

= (1/n) ~x;.
i=l

60

It is also contemplated that an alternative measure of EMG

variability may be used. An abnormality threshold for the
EMG signal variance occurring during REM sleep may be
established based on the EMG variance observed during the
NREM portion of sleep. For example, the abnormality threshold may be set at four times the 5th percentile of the variance
observed during the NREM time intervals. Normally, EMG

65

In some embodiments, the percentage of REM mini-epochs with variance above the selected threshold is computed
as a metric for assessing RBD. The percentage of all REM
mini-epochs with variance above this threshold is also
referred to in the present disclosure as the Supra-Threshold
REM EMG Activity Metric (STREAM), which may be determined for each patient. A score for each patient may be
calculated as a REM sleep duration-weighted average of
results over the course of two or more nights. However,
STREAM may also be determined based on one night of
recording, part of one night, or multiple nights. Other methods and techniques that compare and/or contrast the variability of the EMG signal in REM sleep versus NREM sleep may
be used. These other methods and techniques may be used to
establish a threshold for assessment of RBD. Thus, various
means for determining the variability of the EMG signal
between REM and NREM sleep can be used in the present
methods and systems.
With reference to FIG. 1, a flowchart is shown that diagrams a method for diagnosing and assessing rapid eye movement sleep behavior disorder (RBD) in a patient. With respect
to reference numeral 100, one or more physiological signals
of a patient are measured during REM and NREM sleep
intervals. These physiological signals may include signals
obtained using one or more of the following: electroencephalogram (EEG), electromyogram (EMG), electrooculogram
(EOG), electrocardiogram (ECG), snoring, respiratory effort,
airflow at the nose and mouth, pulse oximetry, and combinations thereof. In addition to these, other physiological signals
that differ between wakefulness, REM sleep, and NREM
sleep may be suitable for use in the method; for example,
other physiological signals indicative of muscle activity may
be used. Signals may also be obtained from multiple locations
using the same technique. For example, EMG signals may be
measured at the chin, forearm extensor compartments, and
the anteriortibialis muscles bilaterally, including surface and/
or subsurface measurement.
With respect to reference numeral 110, the physiological
signal may be filtered to reduce background noise and/or to
select particular frequencies for analysis. Specific EMG frequency bands may prove more useful than others. For
example, the lower frequency bands (e.g., 10 to 15 Hz) may
be more useful in some cases, and even frequencies lower
than 10 Hz may be used.
With respect to reference numeral 120, the time-evolution
of the variance is determined for the EMG signal within at
least one REM sleep time interval and the background level of
the variance is determined for the EMG signal within at least

US 7,996,076 B2
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one NREM sleep time interval. These variances may determined by using the formula:

The processor 250 includes a software-implemented algorithm capable of determining a rapid eye movement (REM)
variance for the physiological signals within at least one REM
sleep time interval and a non-rapid eye movement (NREM)
variance for physiological signals within the at least one
NREM sleep time interval, establishing a threshold based on
the NREM variance, and calculating a percentage of REM
sleep time intervals with variance above the threshold. The
time-evolution of the variance may be determined for the
EMG signal within at least one REM sleep time interval and
the background level of the variance may be determined for
the EMG signal within at least one NREM sleep time interval.
It is to be understood that only the relevant steps of the
algorithm are discussed in relation to FIG. 1, but that other
software-implemented instructions may be needed to control
and manage the overall operation of the system. The algorithm or portions of the algorithm may be stored on one or
more types of computer-readable medium associated with the
instrument 220 and/or the processor 250.
The processor 250 also includes a signal output device to
output to a user the REM and NREM variances, the threshold,
and/or the calculated percentage of REM sleep time intervals
with variance above the threshold. As shown in FIG. 2, the
output device may be the screen of the laptop computer. The
output may also be stored or transmitted via a network to a
remote user. The processor 250 may include multiple algorithms that perform various methods described by the present
disclosure.
Methods and systems employing the algorithm, performance and output of the algorithm, and determination of one
or more STREAM values are illustrated by application of
these methods and systems to a group of23 subjects. Subjects
(n=23) may be identified and recruited as described by Consens et al. in "Validation of a polysonmographic score for
REM sleep behavior disorder" Sleep 2005; 28(8):993-997.
Seventeen subjects are patients and six are control subjects.
The seventeen patients carried diagnoses of multiple system
atrophy (MSA, n=5), Parkinson's disease (PD, n=6), dementia with Lewy bodies (DLB, n=2), progressive supranuclear
palsy (n=3), and sporadic olivopontocerebellar atrophy
(n=l). Patients with progressive supranuclear palsy are
included to have a group of patients with a neurodegenerative
disorder causing Parkinsonian symptoms unassociated with
RBD, for comparison with the MSA, PD, and DLB patients.
Diagnoses are established by board-certified neurologists
who specialize in neurodegenerative disorders. A consultation with sleep medicine specialists may be included as part of
the protocol. Normal control subjects, without any specific
sleep complaints and with no genetic relationship to the
patients, had similar age and sex distributions to those of the
patients.
Histories, physical examinations, and polysonmograms
are performed as follows. Sleep-oriented clinical histories are
performed by either of 2 physicians, board-certified in both
sleep medicine and neurology, who are masked to any questionnaire and polysonmographic data. Based on widely-used
clinical criteria (as described in American Sleep Disorders
Association, "International classification of sleep disorders,
revised: Diagnostic and coding manual," Rochester, Minn.:
American Sleep Disorders Association, 1997), which at that
time did not require polysonmography to assess for RBD, the
likelihood of the diagnosis is rated as probable (2), possible
(1 ), or unlikely (0). Patients with a history of frequent, clear
dream enactment are rated as "probable," those without nocturnal behavioral episodes as "unlikely," and those with such
episodes that are not clearly dream enactment are rated as
"possible." Seven subjects had a clinical impression of prob-

N
CT=

5

1/(N -1) ~(x; -xi
i=l

wherein a is the variance, N is the number of samples in the
time interval, x, is the ith sample of the signal in the time
interval, and x is signal in the time interval. Alternatively,
variances may be determined by calculating the sum of the
square amplitudes of the physiological signals within the
REM sleep time interval. Other techniques for computing the
variability of the signal over time are contemplated by this
disclosure.
With respect to reference numeral 130, a threshold is established based on the NREM variance. For example, the threshold can be set as the upper limit for the physiological signal
background during REM sleep, with the upper limit being
about two to about six times the 5th percentile of the NREM
varrnnce.
With respect to reference numeral 140, a percentage of
REM sleep time intervals with variance above the threshold is
calculated. For example, where the signals are EMG signals,
the method includes calculating the Supra-Threshold REM
EMG Activity Metric (STREAM). In addition, various EMG
signals may be used, such as EMG signals other than surface
chin EMG. The EMG may be recorded from any muscle or
multiple muscles, and by means other than surface recordings. It should be appreciated that the calculations described
for STREAM in the present disclosure can be applied to
determine analogous metrics for various other techniques that
measure physiological signals indicative of muscle activity.
Thus, when the present disclosure contemplates methods or
systems using STREAM, these analogous metrics for muscle
activity may be included in addition to or substituted for
STREAM.
The percentage or proportion calculated at reference
numeral 140 may be used to classify the patient as a candidate
for rapid eye movement sleep behavior disorder (RBD), as
indicated at reference numeral 150. Alternatively, or in addition to, as shown at reference numeral 160, the percentage or
proportion may be used in conjunction with other assessments of RBD, such as visual PSG scoring and/or clinical
impressions collected via questionnaires, for example. Alternatively, the percentage or proportion may simply be used as
a continuous score for characterization of the subject's physiologic RED-tendency, rather than as a dichotomous score to
label a patient as having or not having RBD.
With reference to FIG. 2, a system is shown for diagnosing
and assessing rapid eye movement sleep behavior disorder
(RBD) in a patient. The sleeping patient 200 is connected 210
to an instrument 220 that acts as a signal input device to
collect one or more physiological signals, for example an
electromyograph. The physiological signals may be processed in some manner by the instrument 220. For example,
the instrument 220 may filter particular signal frequencies.
The instrument 220 (or signal input device) is connected to a
processor 250, which as shown in FIG. 2 may be part of a
laptop computer. Alternatively, the instrument 220 that collects the signals and the processor 250 may be a single unit,
where as shown by reference numeral 240, the physiological
signals from the patient 200 are received directly by the
combination processor 250 and signal input device.
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able RBD, and for purposes of analyses these are combined
with the two subjects who had possible RBD.
Bed partners completed a questionnaire that asked for Likert scale ratings for each of the symptoms that are diagnostic
criteria for RBD, as per American Sleep Disorders Association, "International classification of sleep disorders, revised:
Diagnostic and coding manual," Rochester, Minn.: American
Sleep Disorders Association, 1997. Results are tallied and
averaged to determine an overall RBD symptom score that
could range from Oto 1.0.
All subjects underwent laboratory-based polysonmography (PSG) for two consecutive nights. Digital recordings
included electroencephalogram (EEG) (C3-A2, C4-Al,
O1-A2, O2-Al by International 10-20 system), chin electromyogram (EMG), electrooculogram (EOG), electrocardiogram, snoring, respiratory effort using piezoelectric belts
over the chest and abdomen, airflow at the nose and mouth
using thermocouples, and pulse oximetry. Surface EMGs are
recorded from the forearm extensor compartments and the
anterior tibialis muscles bilaterally. The data are collected
using Telefactor digital polysonmography equipment (Conshohocken, Pa.). The EMG is recorded with a 10 Hz high-pass
filter and a 60 Hz notch filter, and sampled at 200 Hz. A digital
10-70 Hz band pass filter is applied to the EMG data before
subsequent computer processing. Experienced polysonmographic technologists masked to patient diagnoses applied the
electrodes, monitored the studies continuously, and monitored the subjects by continuous video observation.
Polysomnograms are scored manually according to a standard protocol, as described in Rechtschaffen A, Kales A, "A
manual of standardized terminology, techniques and scoring
system for sleep stages of human subjects," Los Angeles:
Brain Information Service/Brain Research Institute, UCLA,
1968. In addition, one senior registered polysonmographic
technologist masked to patients' clinical data manually (visually) scored PSG measures of RBD in accordance with the
approach described by Lapierre 0, Montplaisir J., "Polysomnographic features of REM sleep behavior disorder: Development of a scoring method," Neurology 1992; 42:13711374. The approach is based on two measurements: the
proportion of 20-second REM sleep epochs that contain a
predominance of abnormally elevated background chin
muscle tone (tonic component), and the proportion of 2-second mini-epochs (within 20-second REM sleep epochs) that
show bursts of EMG activity (phasic component). Identical
measures are used with the present methods, except that the
epochs to assess tonic activity are 30 seconds in duration (a
more widely used standard), and the mini-epochs to assess
phasic activity are 3 seconds in duration. Each REM sleep
epoch is scored as tonic or atonic depending on whether tonic
chin EMG activity is present for more or less than 50% of the
epoch.
"Percent phasic" and "percent tonic" scores for each subject are computed as a REM sleep duration-weighted average
of the results from the two nights, in a manner that essentially
considered the data from the two recordings as if they are
obtained from one long night. The percent phasic and percent
tonic scores are then averaged to obtain an overall "PSG
score" that reflects results of the visually-assessed method
described by Lapierre 0, Montplaisir J., "Polysonmographic
features of REM sleep behavior disorder: Development of a
scoring method," Neurology 1992; 42:1371-1374.
A computer algorithm is used to calculate the variance of
the chin EMG signal during all 3-s mini-epochs within each
PSG. The variance a is computed as:
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where N is the number of samples in the interval, x, is the ith
data sample in the interval, and xis the mean of the samples
in the interval. If the variance calculation is replaced by the
sum of the square amplitudes, similar results may be
obtained. However, the variance calculation is used to generate the results presented. An upper limit for normal EMG
background activity during REM sleep is defined as four
times the 5th percentile of the variance observed during all
NREM epochs. Normally, EMG tone during REM sleep
should not exceed the lowest tone noted during NREM sleep,
operationalized here as the 5th percentile of the NREM EMG
variance. To identify activity likely to be abnormal, with
reference to NREM EMG tone, a cut-off at 4 times the 5th
percentile is initially tested. Other cut-offs may perform similarly; e.g., 2 to 6 times the 5th percentile. The percentage of
REM mini-epochs with variance above the selected threshold
is computed as the new metric, referred to as the SupraThreshold REM EMG Activity Metric (STREAM). Since
STREAM is the percentage of REM mini-epochs with variance above the selected threshold, it does not have units. A
score for each subject is calculated as a REM sleep durationweighted average of the results from the 2 nights.
Associations are tested for significance with the nonparametric Spearman correlation coefficient rho, to avoid the
assumption that underlying distributions of variables were
normal. Receiver-operator curves were used to assess performance of the new metric in comparison to the visual methods
of Lapierre and Montplaisir. The level of statistical significance is set at p<0.05.
Results are as follows. The 23 subjects had a mean age of
63± 10 ( s.d.) years and 12 were women. Table 1 below shows
for each subject the RBD PSG score, EMG variance on each
night, overall EMG variance score, STREAM on each night,
overall RBD symptom score, and clinical impression based
on criteria established by the International Classification of
Sleep Disorders (ICSD). The mean STREAM was
22.59±19.42. An example of EMG variance results during
one 30-second epoch is shown in FIG. 3. The change in EMG
variance through the night is illustrated in FIG. 4 for two
representative subjects, one with and one without RBD based
on clinical impression. For the patient without RBD (FIG. 4
panel A, in red), the computed EMG variance is generally
below the threshold during REM sleep, whereas for the
patient with RBD (FIG. 4 panel B, in green), the EMG variance often exceeds the threshold.
FIG. 3 graphically illustrates a thirty-second epoch of
REM sleep recorded from subject 7 (upper panel), along with
a corresponding plot of calculated EMG variance for each
3-second mini-epoch (lower panel); LOC-A2 and ROC-Al
are left and right electro-oculograms; Chinl-Chin2 is the
submental EMG signal; C3-A2, C4-Al, O1-A2, and O2-Al
are left central, right central, left occipital, and right occipital
EEG derivations; the dashed line labeled "Threshold" is
placed at 4 times the 5th percentile value of non-REM chin
electromyographic variance for this particular subject;
FIG. 4 graphically illustrates electromyographic variance
computed over 3-second mini-epochs though the night (A)
for a subject without a clinical diagnosis ofRBD (subject 17),
and (B) for a subject with a clinical diagnosis ofRBD (subject
2); NREM (blue) signifies values associated with non-REM
mini-epochs; REM<THRES (red) indicates REM mini-ep-
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ochs with EMG variance values less than the 4 times the
non-REM 5th percentile threshold, and REM>THRES
(green) indicates REM epochs with EMG variance greater
than the threshold;

derived PSG score (rho=0.42, p=0.048). RBD symptom
scores derived from an International Criteria for Sleep Disorders-based questionnaire are plotted against the computergenerated STREAM score (A) and the visually-generated

TABLE 1
Summary ofRBD Measures for Each Subject*
STREAM
(2-night weighted
Subject PSG Score STREAM Night 1 STREAM Night 2
average)

2
3

4
5
6
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23

11.86
59.34
57.45
14.25
43.14
68.20
50.92
37.26
5.88
64.99
59.16
0.72
9.14
9.96
46.30
12.76
1.98
14.79
10.24
2.03
5.19
3.64
6.23

8.82
5.96
14.67
37.87
45.79
50.28
47.83
26.43
21.65
54.62
82.07
1.98
3.33
7.21
32.10
2.91
2.05
21.26
3.43
5.45
13.18
8.05
9.84

11.25
63.70
15.27
13.80
54.00
46.67
52.06
12.32
15.97
37.86
59.90
0.99
15.54
4.80
27.34
94.26
2.86
5.39
4.45
1.75

4.76
3.83
11.06

10.41
38.28
15.22
23.39
49.39
49.55
50.55
20.13
18.85
44.26
72.20
1.43
15.06
5.71
29.67
26.18
2.48
14.99
4.01
3.28
8.64
5.38
10.43

ICSD-Based
Clinical
Impression

RBD
Symptom
Score

0
2
2
2
2
0

0.586
0.623
0.643
0.586
0.671
0.308
0.521
0.29
0.41
0.65
0.21
0.353
0.532
0.35
0.79
0.592
0.275
0.21
0.241
0.208
0.28
0.583
0.208

0
0
2
0
0
0
2
2
0
0
0
0
0
0
0

*RED = REM sleep behavior disorder; PSG = polysomnogram; STREAM= supra-threshold REM electromyographic (EMG)
activity metric; ICSD = International Classification of Sleep Disorders.

As shown in FIG. 5, the variance-based STREAM correlates well with the visually-derived PSG score for RBD severity (Spearmanrho=0.85, p<0.0001 ). The result is similar even
if the analysis is confined to the 17 subjects with neurodegenerative disorders (rho=0.82, p=0.0001 ). A clinical impression
ofRBD (probable or possible, n=9 subjects) is associated to a
similar extent with both the computer-generated STREAM
(Wilcoxon rank sum test, p=0.0089) and the visually-derived
PSG score (p=0.0182). Subjects without a clinical diagnosis
of RBD are indicated by circles (o), and the subjects with a
clinical diagnosis of possible or probable RBD are indicated
by crosses (x);
FIG. 6 shows that both the STREAM and the PSG score
effectively separate subjects with and without an ICSD-based
clinical impression of probable or possible RBD. Using the
optimal threshold levels (12% for the PSG score and 14% for
the EMG variance score) the methods have sensitivities of
89% for the PSG score and 100% for the STREAM, and
specificity of71 %, with 78% (18 of the 23) patients classified
correctly using the PSG score and 83% (19 of 23) patients
classified correctly using the STREAM. Panel A illustrates
the computer-generated EMG variance score and Panel B
illustrates the visually-generated PSG score (B), where both
show similar ability to separate subjects for whom RBD was
considered probable or possible (1) or unlikely (0) by clinicians who interviewed and examined the subjects; box plots
show median, 25th and 75th percentiles as horizontal lines;
the whiskers extend from the box out to 1.5 times the interquartile range of the data; the'+' marks show outliers; panel
(B) is adapted from methods and described in Example A.
As depicted in FIG. 7, the RBD symptom score correlates
to a similar extent, though not strongly, with the computergenerated STREAM (rho=0.42, p=0.046) and the visually-
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PSG score (B). Subjects without a clinical diagnosis ofRBD
are indicated by circles (o ), and the subjects with a clinical
diagnosis of possible or probable RBD are indicated by
crosses (x). Two outliers with high STREAM and low RBD
symptom scores appear in FIG. 7A. Review of these polysonmograms shows that in one case, the EMG channel used
by the algorithm shows relatively invariant, high activity
throughout Night 1 that may be in part artifactual. In the
second case, REM sleep is particularly difficult to score
because it often resembled wakefulness. Such challenges can
be common in a sample of patients with RBD. Elimination of
those two outliers from the analysis improves the correlation
between the STREAM and RBD symptom score (rho=0.67,
p=0.0008).
Both the STREAM and the PSG score can be used as
metrics for identifying patients with RBD. A graphical
method of summarizing the detection performance obtained
with these metrics is to plot a receiver operating characteristic
(ROC) curve, which summarizes the tradeoffbetween sensitivity and specificity for various threshold levels of the metric.
Sensitivity represents the probability of detecting RBD when
it is present, and specificity represents the probability of not
detecting RBD when it is actually absent. An ROC curve
comparing the empirical detection performance of the
STREAM with the PSG score, for a range of possible threshold values on each measure, reveals similar efficacy for the
two approaches, as shown in FIG. 8. FIG. 8 graphically illustrates the receiver-operator characteristic (ROC) curves for
the STREAM and the visually-generated PSG score, suggesting similar diagnostic utility for the two approaches; the area
under the ROC curves computed using the trapezoidal
method is 0.84 for STREAM and 0.73 for the PSG score.
FIG. 9 graphically illustrates that the STREAM during
REM sleep on night 1 correlates with STREAM on night 2
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(rho=0.53, p=0.0098); subjects without a clinical diagnosis of
RBD are indicated by circles (o ), and the subjects with a
clinical diagnosis of possible or probable RBD are indicated
by crosses (x). Among all subjects, the computed STREAM
on Night 1 correlates well with the STREAM on Night 2
(rho=0.53, p=0.0098; FIG. 9A); however, this correlation is
not as high as that observed for Night 1 and Night 2 visuallyderived PSG scores (rho=0.92, p<0.0001 ). The score from the
second night, in comparison to that of the first night, seems to
show stronger associations with clinical measures. Specifically, the second night STREAM effectively separates subjects with and without an ICSD-based clinical impression of
probable or possible RBD (Wilcoxon rank sum test,
P=0.0028), whereas the first night STREAM does not (Wilcoxon rank sum test, P=0.361, FIG. 9B). Similarly, the second night STREAM shows a significant correlation with the
RBD symptom score (rho=0.52, P=0.011 ), but the first night
STREAM does not (rho=0.18, P=0.409, FIG. 9C).
The value of the specific EMG frequency content used to
compute STREAM is demonstrated by repeating the analyses
using narrower, digitally filtered EMG frequency bands. The
results, surmnarized in Table 2 below, suggest that the
STREAM computed from lower frequency components of
the EMG signal may provide a better association with clinical
measures.

in-home sleep studies, where objective evidence for RBD
may improve assessment of patients suspected to have RBD,
conditions strongly associated with RBD (such as Parkinson's disease, multiple system atrophy, and narcolepsy), or
sleep disorders sometimes associated with RBD (such as
restless legs syndrome and obstructive sleep apnea).
Some previous attempts to quantify visual scoring of REM
EMG activity have focused on bursts of phasic REM activity.
"Phasic" refers to rapid eye movements during REM sleep.
Such approaches that focus on phasic bursts of muscle activity have identified 5.0 to 12.5% of phasic REM sleep as
containing these bursts. The STREAM often identifies higher
proportions of REM sleep as having excessive tone, even in
most subjects without RBD, and the percent of mini-epochs
thus identified on any given night reached a maximum of
81 %. These observations suggest that STREAM may assess
bursts of activity (see FIG. 3) somewhat smaller in amplitude
than those assessed using visual scoring methods. One important advantage of STREAM in comparison to other
approaches is that it obviates the need for somewhat arbitrary
distinction of tonic and phasic types of motor activity.
Other features of the present methods employing the automated algorithm that may facilitate assessment ofRBD features include the automatic identification of a scoring threshold specific to each subject, based on his or her lowest NREM
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TABLE2
Dependence of STREAM, and its Associations with Clinical Measures, on EMG Frequency.

EMG
Frequency

STREAM
Combined Nights

Content Hz

mean± SD

10-70
10-14.9
15-19.9
20-24.9
25-29.9
30-34.9
35-39.9
40-44.9
45-49.5
50-54.9
55-59.9
60-64.9
65-70

22.59
23.58
22.50
23.38
27.98
30.33
29.90
29.31
30.29
30.15
29.26
29.10
31.41

±
±
±
±
±
±
±
±
±
±
±
±
±

19.42
20.62
18.24
18.08
20. 74
22.99
23.51
23.11
23.01
22.61
23.15
23.52
23.85

IC SD-Based
Clinical Impression
(Rank Sum Test) P - value
Comb.

!"Night

2 nd Night

0.0089
0.0128
0.0153
0.0253
0.0215
0.0215
0.0547
0.0631
0.0726
0.0631
0.0298
0.0298
0.0406

0.3610
0.2439
0.5923
0.7290
0.5923
0.3289
0.3289
0.3610
0.3610
0.2439
0.2193
0.1227
0.2193

0.0028
0.0128
0.0061
0.0051
0.0128
0.0128
0.0215
0.0253
0.0182
0.0153
0.0182
0.0182
0.0253

Spearman
Correlation of
1st and 2nd
Night STREAM

RBD Symptom Score
(Spearman Correlation)
rho P - value
!"Night

Comb.
0.42
0.60
0.48
0.39
0.38
0.38
0.29
0.28
0.27
0.27
0.32
0.32
0.31

Embodiments of the present methods applied to the sample
of patients with neurodegenerative disorders and control subjects demonstrates that computerized analysis ofEMG variance during sleep quantifies polysonmographic evidence of
RBD about as effectively as did a previously validated and
commonly used visual scoring method. Both approaches
appear to be effective in separating subjects with RBD from
subjects without RBD. Major differences between the present
methods employing computerized analysis as compared to
visual RBD scoring, include the following: the present methods produce results in seconds rather than 1-3 hours for typical visual scoring; no previous experience in specialized RBD
scoring is required for the present methods; the present methods may provide substantial cost savings; and the present
methods may eliminate concerns over test-retest, inter-scorer,
or inter-laboratory reliability. The automatic computation of
STREAM may be used in research settings requiring quantification of polysonmographic evidence for RBD. The algorithm also may prove useful in clinical laboratory-based or

(0.046)
(0.0026)
(0.0194)
(0.0639)
(0.0768)
(0.0755)
(0.1745)
(0.1951)
(0.2208)
(0.2102)
(0.1393)
(0.1419)
(0.1582)
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0.18
0.39
0.24
0.11
0.04
0.12
0.15
0.08
0.10
0.15
0.15
0.17
0.13

(0.4086)
(0.0650)
(0.2704)
(0.6277)
(0.8402)
(0.5804)
(0.4922)
(0.7013)
(0.6551)
(0.4994)
(0.4808)
(0.4284)
(0.5558)

2nd Night

0.52
0.60
0.45
0.47
0.45
0.43
0.39
0.37
0.42
0.40
0.39
0.38
0.37

(0.0111)
(0.0025)
(0.0296)
(0.0244)
(0.0314)
(0.0405)
(0.0635)
(0.0842)
(0.0456)
(0.0579)
(0.0635)
(0.0723)
(0.0824)

rho (p - value)
0.53
0.71
0.42
0.39
0.49
0.58
0.77
0.78
0.78
0.83
0.81
0.83
0.84

(0.0098)
(0.0002)
(0.0461)
(0.0680)
(0.0180)
(0.0045)
(<0.0001)
(<0.0001)
(<0.0001)
(<0.0001)
(<0.0001)
(<0.0001)
(<0.0001)

muscle activity. A subject's discomfort, restlessness, periodic
leg movements, sleep apnea, or immobility (e.g., secondary
to Parkinson's disease) could well affect average EMG variance. So could the quality of the connection between the
EMG electrode and the skin over the muscle to be recorded.
Hence, the REM EMG-scoringthresholdmay be based on the
5th percentile (low end) of the non-REM variance for the
specific individual and his or her specific sleep study to assure
that only minimum non-REM muscle tone during quiet sleep
is used in all cases to determine the threshold for excessive
REM sleep muscle tone.
The so-called "first night effect" in polysonmography may
affect REM sleep prominently and might explain the observation that the second night of polysonmography, in comparison to the first night, seems more useful in automatic assessment for RBD. The original approach was to combine data
from the 2 nights because REM sleep can be brief or difficult
to score in older patients and especially those with neurodegenerative conditions. Two nights of diagnostic recording are
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already advocated by some for patients suspected to have
parasonmias. The present data support this approach, or else
a habituation night of unrecorded sleep in a laboratory setting
prior to the actual recording.
Several modifications to the EMG variance algorithm are
possible. For example, the decision to use four times the
non-REM 5th percentile for EMG variance as the threshold
during REM sleep produces a reasonably wide spread of
results between subjects with and without RBD, but other
thresholds may be used to increase or decrease the spread.
Moreover, whereas one chin EMG derivation is used for each
subject, more selective attention to the derivation with the
best signal quality may improve results, for example as suggested by the review of outlier data. Alternative sites, in
addition to or in combination with the chin site, may also be
used for recording the surface EMG. The chin can be a good
initial choice because the differences in muscle tone during
REM and NREM sleep at this site can be greater than those
recorded over muscles in any extremity. For example, exploration of other sites shows a correlation with clinical measures for the left anterior tibialis as a recording site. Thus, the
present algorithms and thresholds may be optimized for use at
one or more sites.
In some embodiments, the present methods and systems
may be applied to patients with idiopathic RBD. For example,
patients with idiopathic RBD may develop one of the neurodegenerative conditions examined using the present methods
and RBD manifestations in patients with and without neurodegenerative conditions are largely indistinguishable. In
some embodiments, the present algorithm does not exclude
EMG bursts at the termination of apneic events, and in other
embodiments the method and algorithm performance may be
enhanced if such EMG bursts are excluded. Additionally, in
some embodiments specific EMG frequency bands may
prove more useful than others. For example, the lower frequency bands examined (e.g., 10 to 15 Hz) appear to be more
useful, and frequencies lower than 10 Hz may perform better
in some embodiments.
The present disclosure also includes the following features.
The patient and study-specific non-REM sleep EM G variance
can be used to determine a threshold above which REM sleep
EMG tone should not normally rise; that this level of activity
is computed automatically by the algorithm; and that the
diagnosis of RBD (or identification of REM sleep without
atonia) can be facilitated by analysis of the frequency with
which the EMG minimum variance threshold established during non-REM sleep is in fact exceeded during REM sleep. In
some embodiments, the effective quantitative analysis of the
EMG during REM sleep can be performed with one single
assessment of EMG activity, rather than the two separate
assessments that are employed visually in traditional, manual
assessments of polysonmograms for evidence ofRBD. Other
approaches-either non-quantitative as described in the
International Classification of Sleep Disorders or quantitative
but visual and subjective as described by LaPierre and Montplaisir (Neurology, 1992)-all rely on separate assessments
of REM sleep-associated discrete bursts ofEMG activity and
baseline EMG tone. In the present methods, one single synthesized quantitative assessment of EMG variance during
REM sleep may be as effective as the more complicated dual
approach, which appears to be unnecessary.
The present methods include polysonmographic assessment for REM sleep behavior disorder (RBD). These methods may be used in conjunction with visual scoring methods
which are reliable but require slow, labor-intensive visual
scoring of surface electromyogram (EMG) activity. The
present methods and systems may include a computerized

metric to assess EMG variance where this metric may be used
alone or in conjunction with results from visual scoring, bed
partner-rated RBD symptom scores, and/or clinical assessments by sleep medicine specialists.
The present methods correlate well with visual quantitative
scoring methods. Nocturnal polysonmograms are acquired
for each subject. A computer algorithm calculates the variance of the chin EMG during all 3-second mini-epochs, and
compares variances during REM sleep to a threshold defined
by variances during quiet non-REM (NREM) sleep. The percentage of all REM mini-epochs with variance above this
threshold creates a metric, which is referred to as the suprathreshold REM EMG activity metric (STREAM) for each
subject. The STREAM correlates highly with the visuallyderived score for RBD severity (Spearman rho=0.87,
P<0.0001). A clinical impression of probable or possible
RBD was associated to a similar extent with both STREAM
(Wilcoxon rank sum test, P=0.009) and the visually-derived
score (P=0.018). An optimal STREAM cutoff identified
probable or possible RBD with 100% sensitivity and 71 %
specificity. The RBD symptom score correlated with both
STREAM (rho=0.42, P=0.046) and the visual score
(rho=0.42, P=0.048). The present methods and systems for
assessment for RBD provide as much or more utility as compared with the more time-consuming manual visual scoring
approach.
The present methods and systems include providing EMG
scoring methods in order to distinguish RBD patients from
control subjects. In some embodiments, these methods may
be used to validate other methods or may be performed in
combination with features of other quantitative methods as
described by Lapierre 0, Montplaisir J., "Polysomnographic
features of REM sleep behavior disorder: Development of a
scoring method," Neurology 1992; 42:1371-1374, including
those methods as described in Examples 1 and 2. For
example, the present methods and systems may be combined
with those described by Consens F B, Chervin R D, Koeppe
RA et al., "Validation of a poly sonmographic score for REM
sleep behavior disorder," Sleep 2005; 28(8):993-997 that
demonstrate the diagnostic validity of the polysomnographic
score. The present methods therefore may serve to augment or
replace limitations of such visual scoring methods, where
using visual scoring methods alone is hampered by subjectivity, time-consumption (typically adding 1-3 hours to total
scoring time), expense, and where visual scoring is feasible
only after considerable practice by an experienced technologist.
The present methods and systems include a computer algorithm that compares EMG variance during REM and NREM
sleep and generates a score predictive of RBD symptoms,
ICSD-based diagnoses, and visual polysonmographic findings. These methods and systems reduce time and labor and
increase reliability of efforts to identify or quantify RBD
features on polysonmography. These methods and systems
may be used for clinical diagnosis or assessment for RBD or
for evaluation of patients who have conditions in which the
risk ofRBD is increased. In some cases, the present methods
and/or combination of methods can provide EMG scoring
that distinguishes RBD patients from control subjects.
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Example 1 illustrates quantitative visual scoring methods
that may be used comparatively or in conjunction with the
present methods that include an algorithm that compares
EMG variance during REM and NREM sleep and generates a
score predictive ofRBD symptoms, ICSD-based diagnoses,
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and visual polysomnographic findings. These visual scoring
methods include methods and modifications of the methods
as described by Consens F B, Chervin RD, Koeppe RA et al.,
"Validation of a poly somnographic score for REM sleep
behavior disorder," Sleep 2005; 28(8):993-997.
Subjects are selected as follows. Patients have diagnoses of
multiple system atrophy (MSA), Parkinson disease (PD),
dementia with Lewy bodies (DLB), progressive supranuclear
palsy (PSP), or sporadic olivopontocerebellar atrophy
(OPCA). Diagnoses are made by board-certified neurologists
who specialize in neurodegenerative disorders. The patients
are volunteer participants in a National Institutes of Healthfunded study of RBD in the a-synucleinopathies, including
MSA, PD, and DLB. They are recruited from the ataxia,
movement disorders, and cognitive disorders clinics at the
Department of Neurology, University of Michigan. Subjects
are recruited sequentially from these clinics if they met criteria for diagnosis; indicated interest in the research study;
and signed a consent form or, if demented, had a consent form
cosigned by the next of kin or legal guardian. The patients had
not previously been referred to a sleep disorders center, and a
consultation with sleep experts is included as part of their
study. Patients with PSP are included to have a group of
patients with a neurodegenerative disorder causing parkinsonian symptoms unassociated with RBD, for comparison with
the MSA, DLB, and PD patients. For comparison to patients
with neurodegenerative disorders, normal control subjects
with a similar age and sex distribution are included. The
controls are individuals not genetically related to the patients
but still interested in participating in the study. Control subjects have no neurodegenerative disease. They are recruited
from the community and not specifically selected for any
sleep complaints. For the most part they shared the same
environment as the subjects (significant other, friend, church
member, etc.).
The clinical interview of patients is as follows. Subjects are
admitted to the General Clinical Research Center Sleep Disorders Laboratory, where they undergo a complete history
and physical examination. A comprehensive evaluation of
their sleep history is performed by either of 2 neurologists
who are each diplomates of the American Board of Sleep
Medicine and the American Board of Psychiatry and Neurology. Based on the International Classification of Sleep Disorders (ICSD) entry for RBD, the physicians generate an
overall clinical impression of whether the likelihood of RBD
is probable, possible, or unlikely. Because evidence-based
definitions of these states do not exist, this rating represents a
Likert scale only. In general, patients with a history of frequent, clear dream enactment are rated as "probable," those
with no history of such episodes as "unlikely," and those with
behavioral episodes that are not clearly repeated dream enactment are rated as "possible." At the time of the interview, the
clinicians are masked to questionnaire and polysomnographic results but not to any medical history.
The questionnaire information includes the following. All
subjects received a questionnaire to be completed by the bed
partner. Symptom items reflected each criterion listed in the
ICSD; see Table 3 below. When no partner is available, the
subjects themselves are asked to complete the questionnaire.
Responses for symptom items, which have different numbers
of response levels in some cases, are expressed as a proportion of the maximal item value: each response therefore varied from O (denied) to 1 (fully endorsed). For example, a
response of 2 on item E is converted to a value of 0.50,
whereas a response of 2 on item B is converted to a value of
0.25. The average score on all question items then was used as
the overall RBD symptom score.

TABLE3
Questionnaire That Bed Partners Used
to Rate The Severity ofRBD.
ICSD
Criterion

Scale

A

1-5

B or

1-5

C-1

1-5

C-2
C-3

1-5
1-5

D

1-4

E

1-3
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Question item
My bed partner has a problem with violent
or injurious behavior during sleep
My bed partner moves his/her arms, legs,
body during dreams
My bed partner's behavior during sleep is
harmful or potentially harmful
My bed partner appears to act out dreams
My bed partner's behaviors during sleep
disrupt his/her sleep
How much discomfort does your bed partner's behavior cause you?
What is the duration of your bed partner's
symptoms?

In Table 3, RBD refers to REM (rapid eye movement) sleep
behavior disorder; ICSD, International Classification of
Sleep Disorders. Scales for itemsA-C3 ranged from (1) never
to (5) nightly; for item D, from no discomfort (1) to severe
discomfort (4); for item E, from less than 1 month (1) to more
than 6 months (3).
Sleep studies include the following. All subjects are studied on 2 consecutive nights with laboratory-based polysomnography (PSG). Digital recordings include electroencephalogram (C3-A2, C4-Al, O1-A2, O2-Al by International
10-20 system), chin EMG, electrooculogram, electrocardiogram, snoring, respiratory effort using piezoelectric belts
over the chest and abdomen, and airflow at the nose and
mouth using thermocouples. Bilateral surface EMGs from
the arms (with electrodes placed over the forearm extensor
compartment) and legs (with electrodes placed over the anteriortibialis muscles) are also recorded. Oxyhemoglobin saturation is monitored by pulse oximetry and behavior is monitored by continuous video observation. Experienced
polysomnographic technologists masked to patients' diagnoses apply the electrodes and continuously monitor the
recordings.
Scoring includes the following. Polysomnographic technologists use 21-inch-high resolution (1600x1200 pixel)
computer monitors and standard techniques 17 to score
manually all recordings for sleep stages, limb movements and
respiratory events. One senior registered polysomnographic
technologist masked to patients' clinical data scores PSG
measures ofRBD according to the method described by Lapierre 0, Montplaisir J., "Polysomnographic features of REM
sleep behavior disorder: Development of a scoring method,"
Neurology 1992; 42: 1371-1374 (RPSM). Lapierre andMontplaisir suggest that patients with RBD may be distinguished
from normal control subjects with 2 measurements: the proportion of 20-second REM sleep epochs that contain a predominance of abnormally elevated background chin muscle
tone (tonic component), and the proportion of2-secondminiepochs (within 20-second REM sleep epochs) that show
bursts of EMG activity (phasic component). The instant
visual methods employed identical measures except that the
epochs to assess tonic activity are 30 seconds in duration (a
more widely used standard), and the mini-epochs to assess
phasic activity are 3 seconds in duration. Following the
RPSM, each REM sleep epoch is scored as tonic or atonic
depending upon whether tonic chin EMG activity is present
for more or less than 50% of the epoch. No particular exclusions are made when physiologic evidence for REM sleep
may not have occupied the entire epoch, or when an arousal
(for example, after an apnea) occurred during an epoch scored
as REM sleep. After disruption of REM sleep by movement
arousals or by artifact, the continuation of rapid eye move-
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ments, increased motor activity with erratic behavior, or
incongruous vocalizations are used to identify reemergence
ofREM sleep if the electroencephalogram signal is consistent
with REM sleep and alpha frequencies were absent.
Analysis includes the following. Data from both nights of
observation are used to calculate a single weighted mean for
each of the 2 RBD measures. For example, if 60 epochs of
REM sleep are recorded on the first night and 30 epochs on
the second night, the first night is weighted by a factor of 2
relative to the second night. If 20% of the 60 epochs recorded
on the first night and 50% of the 30 epochs on the second night
are abnormal, the weighted average is (0.2x60+0.5x30)/(60+
30)=0.3 or 30%, and not simply the average of20% and 50%,
which is 35%. This approach is identical to analyzing the data
of the 2 nights as if they were obtained from 1 long night.
The RBD measure for the proportion of epochs containing
elevated muscle tone and the measure for the proportion of
miniepochs containing burst activity are then averaged to
obtain an overall RBD polysomnographic score. This score is
used in the main analyses: nonparametric Spearman correlations that test for associations with the RBD symptom score,
and t tests that assess for associations with the ICSD-based
clinical impression. The level of significance is set at P<0.05.
Results include the following. The quantitative visual scoring method is applied to 23 patients (12 women) aged48 to 81
years (mean 63±10 [SD]). Seventeen subjects had neurodegenerative diseases, including 1 with OPCA, 2 with DLB, 3
with PSP, 5 with MSA, and 6 with PD. Six normal control
subjects (5 women) are aged 49 to 74 years (mean 53±4).
Only 1 control subject had no partner and therefore completed her own questionnaire.
Table 4 lists subject ages, sexes, diagnoses, and scores for
each RBD measure: polysomnographic, symptom-based, and
overall clinical impression. Only 2 subjects are thought by
clinicians to have "possible RBD," and these subjects therefore are combined with the "probable" group for analyses.
The mean RBD polysomnographic score and component
measures are listed in Table 5.

TABLES
Polysornnograhic RBD Scores, along with Component
Scores: Percentage Phasic and Tonic Measures
5
Polysomnographic
RBD Score
Phasic, %
10 Tonic,%

All subjects
subjects*
(n-9)

RBD
subjects*
(n-14)

Non-RBD
P value

Ttest

25.89 ± 24.22
22.10 ± 17.87
29.67 ± 37.53

39.81 ± 21.88
29.33 ± 19.10
50.29 ± 41.35

16.94 ± 21.85
17.46 ± 16.02
16.42 ± 29.13

0.02
0.12
0.03

Data are presented as mean±SD. *REM (rapid eye movement) sleep behavior disorder (RBD) defined by clinical
impression of possible or probable diagnosis, based on definition in International Classification of Sleep Disorders.
FIG.10 graphically illustrates a quantitative visual scoring
method where the REM (rapid eye movement) sleep behavior
disorder (RBD) polysomnographic score (PSG Score) is plotted against the International Classification of Sleep Disorders-based clinical impression of RBD presence (1) or
absence (0). Plots show median scores (midline), mean
(cross), and 10th, 25th, 75th, and 90th percentiles. The polysomnographic RBD score shows an association with the
ICSD-based clinical impression of RBD (t test, P=0.023;
FIG. 10 ). The tonic component of the overall score also shows
an association with clinical impression ofICSD (P=0.031).
The phasic component is in the expected direction but is not
statistically significant (P=0.122).
FIG. 11 graphically illustrates a quantitative visual scoring
method where the REM (rapid eye movement) sleep behavior
disorder (RBD) polysomnographic score (PSG score) is plotted against the RBD symptom score derived from bed partner
questionnaires (Quest). The overall polysomnographic RBD
score shows a significant association with the RBD symptom
score (Spearman rho=0.42, P=0.048; FIG. 11), as did the
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TABLE4
Summary of Demographic, Diagnostic, and RBD Data.

Subject

Sex

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

M
M
M
M
F
F
M
M
F
M
M
F
F
F
M
M
F
F
F
M
F
F
F

Age,y Diagnosis
81
74
68
65
52
74
60
64
48
53
65
61
69
76
66
78
52
58
49
54
53
57
74

PD
PD
PD
PD
PD
PD
MSA
MSA
MSA
MSA
MSA
PSP
PSP
PSP
DLB
DLB
OPCA
NC
NC
NC
NC
NC
NC

RBD
polysomnographic
score

RBD
symptom
score

11.85
59.33
57.45
14.25
43.14
68.19
50.92
37.36
5.88
64.98
59.16
0.72
9.14
9.96
46.29
12.75
1.98
14.78
10.24
2.03
5.19
3.64
6.23

0.59
0.62
0.64
0.59
0.67
0.31
0.52
0.29
0.41
0.65
0.21
0.35
0.53
0.35
0.79
0.59
0.28
0.21
0.24
0.21
0.28
0.58
0.21

ICSD-based
clinical
Medications
impression* at time of study
0
2
2
2
2
0

L/C,
L/C
L/C,
L/C,
L/C,

venlafaxine
buspirone
pramipexole
pramipexole

SSRI
0
0
2
0
0
0
2
2
0
0
0
0
0
0
0

SSRI

SSRI
SSRI: L/C

bupropion
SSRI

*Clinical impression: likelihood of REM (rapid eye movement) sleep behavior disorder (RBD) was probable 2, possible 1, or
unlikely 0. PD refers to Parkinson disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; DLB, dementia
with Le~ bodies; OPCA, sporadic olivopontocerebellar atrophy; NC, normal control; L/C, levodopa/carbidopa; SSRI, selective
serotonin reuptake inhibitor.
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separate tonic and phasic components of the polysomnographic score (rho=0.49, P=0.018, and rho=0.43, P=0.042,
respectively).
The ICSD-based clinical impression ofRBD shows a close
association with RBD symptom scores (P<0.0001 ). If a cutoff
of 10 or more percentage points on the polysomnographic
RBD score is used to indicate RBD (as suggested by receiveroperator curves), the RPSM in comparison with the clinical
impression gold standard shows a sensitivity of 89% and a
specificity of 57%.
Each of the 23 subjects had some scored REM sleep on
each of the two nights, though the amount ranged from 1.5
minutes to 174.5 minutes. Nonetheless, the tonic, phasic, and
combined (averaged) measures on night 1 correlate closely
with the same measures on night 2 (rho=0.73, P<0.0001;
rho=0.83, P<0.0001; and rho=0.92, P<0.0001, respectively).
The quantitative visual scoring measures of RBD polysomnographic features are valid markers for the target sleep
disorder. Whether RBD is defined by ICSD-based clinical
impressions or by bed-partner symptom ratings, the overall
polysomnographic RBD measure shows an association with
the presence of the disorder and with its severity. Decomposition of the polysomnographic RBD measure into its component parts-tonic and phasic scores-generates similar
results. In addition, the high correlation between polysomnographic RBD measures on nights 1 and 2 reveals little testretest variability. Together, these results suggest that the Lapierre and Montplaisir approach to quantification of RBD
polysomnographic severity is a valid and reliable tool in
clinical practice and research.
The previous edition of the ICSD (1992) does not require
polysomnographic evidence to meet minimal criteria for the
diagnosis of RBD. This supports the use of sleep-specialist
clinical impressions and symptom-rating scales as "goldstandards" against which polysomnographic measures are
compared. The new ICSD (2005) requires polysomnographic
features to confirm the diagnosis. Nevertheless, these polysomnographic features remain, as in the 1992 edition, subjectively determined. A more quantitative method, such as the
visual REM sleep polysomnographic scoring method
(RPSM), helps to standardize RBD determinations between
clinical laboratories, research sites, and polysomnographers
at any specific site. Using these methods, the cutpoint of 10%
(average of tonic REM percentage and phasic REM percentage) appears to be optimal to define findings suggestive of
RBD. However, larger sample sizes may more precisely
define an alternate or better cutpoint. Investigation of more
healthy individuals may better characterize the normal range
of values generated by the RPSM. However, in clinical practice, the distribution of polysomnographic RBD scores is
more likely to be unimodal than bimodal, and clinical judgment based on clinical findings along with laboratory results,
without a strict cutpoint, may be most useful. In research
studies, a well-defined objective cutpoint may help identify a
homogenous study sample and improve generalizability of
results.
A limitation of quantitative visual scoring is interscorer or
intrascorer reliability. An important challenge in patients with
a-synucleinopathies is to initially identify REM sleep, the
first step in the RPSM. In practice, exceptions to
Rechtschaffen and Kales or American Academy of Sleep
Medicine (2007) scoring rules must sometimes be made to
score REM periods with elevated electromyographic tone
despite clear evidence of rapid eye movements and EEG
activity consistent with REM sleep. It is not clear whether
such exceptions can be made on a reliable basis by different
scorers or upon rescoring by the same individual. This limi-

tation could reduce the effectiveness of either visual, Lapierre
and Montplaisir-based scoring ofRBD features or automated
STREAM. An automatic sleep staging algorithm could
potentially be used to eliminate inter-rater reliability concerns in REM vs. NREM scoring. The potential for inadequate reliability, and the length of time (up to several hours)
required to score nocturnal PSGs with the visual technique,
may be reduced also by using the present methods and systems that include a computer algorithm that compares EMG
variance during REM and NREM sleep and generates a score
predictive of RBD symptoms, ICSD-based diagnoses, and
visual polysomnographic findings.
Another potential limitation of quantitative visual scoring
arises from combining the percentage of phasic and percentage of tonic measures into 1 overall polysomnographic RBD
score. This approach seems logical, when the numbers of
studied patients remain somewhat limited, but 1 measure
could potentially obscure physiologically informative information in the other. Another potential limitation, as in any
initial cross-sectional study, is that results could be sensitive
to potential confounds, difficult to assess within the current
sample size, such as age, sex, duration of illness, severity of
parkinsonian symptoms, or medication status.
RPSM for quantitative visual analysis of polysomnographic RBD features is valid and provides test-retest reliability. The method may be useful in both clinical and
research settings. Cutpoints of 10% or more of REM sleep
spent with elevated background EMG tone or phasic burst
activity suggests a diagnosis ofRBD. This quantitative visual
method to assess the severity of RBD polysomnographic
features is valid and reliable in patients at risk for RBD
because of neurodegenerative disorders.
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EXAMPLE2
Example 2 illustrates quantitative visual scoring methods
that may be used comparatively or in conjunction with the
present methods that include an algorithm that compares
EMG variance during REM and NREM sleep and generates a
score predictive ofRBD symptoms, ICSD-based diagnoses,
and visual polysomnographic findings. These visual scoring
methods include methods and modifications of the methods
as described by Lapierre 0, Montplaisir J., "Polysomnographic features of REM sleep behavior disorder: Development of a scoring method," Neurology 1992; 42: 1371-1374.
Methods include the following. Patients who fulfill the
diagnostic criteria of severe chronic RBD are selected. These
patients were referred to the sleep clinic for nocturnal agitation. They exhibit violent behavior during sleep, starting
approximately 1 hour after sleep onset and recurring up to five
times during the night. These episodes occurred 3 to 7 nights
a week for 1 to 4 years. None of the patients reported confusion upon arousal from these nocturnal events, but all
reported frequent nightmares characterized mainly by threatening situations in which they would either fight or flee. These
nightmares are closely associated with motor behavior
responsible for injuries ranging from bruises to wrist fracture.
Five normal controls paired to RBD patients for age (aged
45 to 66 years, mean 58.4) are also included. These control
subjects have no clinical evidence of sleep disturbance. In
addition, seven patients with idiopathic periodic limb movements in sleep (PLMS) are recorded as controls in order to
compare PLMS distribution in REM and non-REM (NREM)
sleep with that ofRRD patients. Patients and controls are free
of psychiatric disorders and epilepsy and none used psychotropic medication for at least 2 months before the study.
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Investigation of each patient includes a complete neurologic examination by a neurologist, a routine diurnal EEG,
one all-night sleep EEG using Queen Square and parasagittal
montages, and CT. In addition, auditory evoked potentials
and blink reflexes are assessed to evaluate the integrity of
brainstem structures. Results of the neurologic investigation
were normal in every subject except for the presence of soft
cerebellar signs in one patient. Since RBD had started at an
early age (40 years) in this patient, MRI was performed; it
revealed an Arnold-Chiari type I malformation.
RRD patients and controls had 2 nights of PSG recording.
PSG investigation consists of a standard montage for scoring
sleep stages: left and right electrooculograms, submental
EMG, central (C3-A2) and occipital (O2-Al) EEG, and ECG.
Left and right tibialis anterior EMGs are also recorded and
PLMS are scored according to Coleman's criteria (Coleman
RM, "Periodic movements in sleep (nocturnal myoclonus)
and restless legs syndrome," In Guilleminault C, ed., Sleeping
and waking disorders: indications and techniques, Menlo
Park, Calif. Addison-Wesley, 1982:265-295). The PLMS
index represents the number of periodic limb movements per
hour of sleep. During the first night, a nasobuccal thermistor
is used to rule out sleep apneas. Apnea is defined as the
interruption of oral and nasal airflow for at least 10 seconds.
None of the patients or controls exceeded five apneas per hour
of sleep. Treatment consisted of clonazepam at dosages varying from 0.5 to 2.0 mg given between 1 and 2 hours before
bedtime. Two months after the onset of treatment, patients
underwent two additional all-night PSG recordings. Seven
idiopathic PLMS controls paired for age were also studied, in
order to compare PLMS indexes in REM and NREM sleep
with those ofRBD patients.
Sleep stages are scored according to a modified version of
the method of Rechtschaffen and Kales (Rechtschaffen A,
Kales A A, "A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects," Washington, D.C.: US Government Printing Office,
Public Health Service, 1968) using 20-second epochs. Since
muscle atonia is deficient in RBD patients, REM sleep is
scored without submental EMG atonia. The occurrence of the
first rapid eye movement is used to determine the onset of a
REM sleep period. The termination of a REM sleep period is
identified either by the occurrence of specific EEG features
(K complexes, sleep spindles, or EEG signs of arousal), or by
the absence of rapid eye movements during nine consecutive
20-second epochs. The same method is used to score REM
sleep in normal subjects.
The tonic and phasic components of REM sleep are scored
separately. Each 20-second epoch is scored as tonic or atonic
depending on whether tonic chin EMG activity is present for
more or less than 50% of the epoch. Two types of phasic
activity characteristic of REM sleep are scored: REM density
and phasic EMG density. REM density is defined as the
percentage of 2-second mini-epochs of REM sleep containing at least one rapid eye movement. Phasic EMG density is
scored from the submental EMG recording and represented
the percentage of 2-second mini-epochs containing phasic
EMG events. Those phasic EMG events are defined as any
burst ofEMG activity lasting 0.1 to 5 seconds with an amplitude exceeding four times the background EMG activity.
These criteria are used to identify all EMG bursts that clearly
contrast with the background activity. Short EMG bursts (less
than 100 msec) are not counted, in order to exclude the
repetitive discharge from a single motor unit that is found
occasionally in normal individuals and in patients during
REM sleep and is unaccompanied by any movement on the
video recording.
Statistics include the following. A paired t test (two-tailed)
for independent variables is used to compare sleep variables
of RBD and control subjects. A one-tailed t test is used to

compare specific REM sleep features, since the hypothesis
was that RHD patients exhibit more tonic and phasic activity
during REM sleep. A paired t test (one-tailed) is used to
compare data obtained in RBD patients before and aftertreatment with clonazepam. A Wilcoxon-Mann-Whitney test is
performed on variables not normally distributed.
This scoring method shows sensitivity to treatment with
clonazepam. An increased phasic submental EMG density
occurs in RBD patients, but REM density is similar to that of
controls. Clonazepam selectively decreases REM sleep phasic activity but exerts no effect on REM sleep atonia. Periodic
limb movements in sleep (PLMS) occur equally in both REM
and NREM sleep in RBD patients, suggesting that normal
suppression of PLMS in REM sleep is due to motor inhibition.
The description of the invention is merely exemplary in
nature and, thus, variations that do not depart from the gist of
the invention are intended to be within the scope of the invention. Such variations are not to be regarded as a departure
from the spirit and scope of the invention.
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What is claimed is:
1. A method for diagnosing and assessing rapid eye movement sleep behavior disorder (RBD) in a patient, comprising:
measuring at least one physiological signal of the patient
during at least one rapid eye movement (REM) sleep
time interval and at least one non-rapid eye movement
(NREM) sleep time interval;
determining a REM variance for the physiological signal
within the at least one REM sleep time interval and an
NREM variance for the physiological signal within the
at least one NREM sleep time interval;
establishing a threshold based on the NREM variance; and
calculating a percentage of REM sleep time intervals with
variance above the threshold, where the steps of determining, establishing and calculating are executed by a
computer processor.
2. The method of claim 1, wherein the physiological signal
is an electromyogram (EMG).
3. The method of claim 1, wherein the physiological signal
is an electrical potential generated by at least one muscle of
the patient.
4. The method of claim 3, wherein the at least one muscle
is a chin muscle.
5. The method of claim 1, wherein the at least one rapid eye
movement (REM) sleep time interval is a plurality of successive time epochs.
6. The method of claim 5, wherein the time epochs are
about 3 seconds.
7. The method of claim 1, wherein the measuring includes
an automated method for distinguishing REM and NREM
sleep time intervals.
8. The method of claim 1, wherein determining at least one
of the REM variance or the NREM variance includes using
the formula:

55
N
CT=

1/(N -1) ~ (x; -xi
i=l
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wherein:
a is the variance,
N is a number of samples in the time interval,
x, is an ith sample of the signal in the time interval, and
x is mean signal in the time interval.
9. The method of claim 1, wherein determining at least one
of the REM variance or the NREM variance includes deter-
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mining the sum of the square amplitudes of the physiological
partitioning the EMG signal into predefined time intervals;
signal within the at least one REM sleep time interval.
computing a variance for the EMG signal in each time
10. The method of claim 1, wherein establishing a threshinterval using a computer processor, where the variance
old based on the NREM variance includes:
is a measure from a mean value of the EMG signal; and
setting an upper limit for a physiological signal back- 5
computing an indicator of RBD based on the variance
ground during REM sleep, wherein the upper limit is
measures from the EMG signal using a computer proabout two to about six times the 5th percentile of the
cessor.
NREM variance.
21. The method of claim 20, further comprising:
11. The method of claim 10, wherein the upper limit is
establishing an abnormality threshold for the EMG signal
about four times the 5th percentile of the NREM variance.
10
during REM sleep based on variance measures observed
12. The method of claim 1, wherein the measuring at least
during a non-REM portion of the EMG signal; and
one physiological signal of the patient includes signals from
computing a percentage of when the REM portions of the
two or more nights.
EMG signal exceeds the abnormality threshold.
13. The method of claim 1, wherein the measuring at least
22. An automated method for diagnosing and assessing
one physiological signal of the patient occurs following a 15 rapid eye movement sleep behavior disorder (RBD) in a
habituation night of sleep by the patient.
patient, comprising:
14. The method of claim 1, further comprising classifying
recording an electromyogram (EMG) signal while the
the patient as an RBD candidate when the percentage of REM
patient is sleeping;
sleep time intervals with variance above the threshold
partitioning the EMG signal into predefined time increexceeds the threshold during the REM sleep time interval.
20
ments and calculating a variance measure for each time
15. The method of claim 1, wherein measuring at least one
increment;
physiological signal of the patient during at least one rapid
identifying portions of the EMG signal which occurred
eye movement (REM) sleep time interval and at least one
during non-rapid eye movement (NREM) and rapid eye
non-rapid eye movement (NREM) sleep time interval
movement (REM) sleep;
includes filtering the at least one physiological signal.
25
establishing an abnormality threshold for the EMG signal
16. The method of claim 15, wherein the filtering removes
during REM sleep based on variance measures observed
a portion of the physiological signal having frequencies
during a non-REM portion of the EMG signal; and
greater than about 15 Hz and retains a portion of the physicomputing a percentage of when the REM portions of the
ological signals having frequencies less than about 15 Hz.
EMG signal exceeds the abnormality threshold using a
17. An automated method for diagnosing and assessing 30
computer processor.
rapid eye movement sleep behavior disorder (RBD) in a
23. The method of claim 22 wherein establishing an abnorpatient, comprising:
mality threshold further comprises selecting a variance meameasuring a physiological signal of the patient during mulsure at a fifth lowest percentile of variance measures observed
tiple sleep intervals;
during the non-REM portion of the EMG signal and setting
identifying portions of the physiological signal which 35 the abnormality threshold to about four times the selected
occurred during non-rapid eye movement (NREM)
varrnnce measure.
sleep and rapid eye movement (REM) sleep; and
24. The method of claim 22, wherein calculating the variestablishing a threshold for the REM portions of the signal
ance measure includes using the formula:
using the NREM portions of the signal, where the establishing step is executed by a computer processor.
40
N
18. The method of claim 17, wherein the measuring
CT= 1/(N -1) ~ (x; -xi
includes measuring an electromyogram (EMG) signal of the
i=l
patient.
19. The method of claim 17, wherein establishing a threshold includes:
45
wherein:
establishing an abnormality threshold for the EMG signal
a is the variance,
during REM sleep based on variance observed during
N is a number of samples in the time increment,
the NREM sleep portion of the EMG signal; and
x, is an ith signal in the time increment, and
computing a percentage of when the REM portions of the
x is mean signal in the time increment;
EMG signal exceed the abnormality threshold.
50
or,
20. An automated method for diagnosing and assessing
determining the sum of the square amplitudes of the signals
rapid eye movement sleep behavior disorder (RBD) in a
within the time increment.
patient, comprising:
capturing a electromyogram (EMG) signal while the
patient is sleeping;
* * * * *
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